Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation ...Middle East

LUND, Sweden, June 1, 2023 /PRNewswire/ -- Hansa Biopharma, "Hansa" (Nasdaq Stockholm: HNSA), a pioneer in enzyme technology for rare immunological conditions, today announced that it has attained reimbursement in Belgium for its first-in-class treatment, Idefirix, for the desensitization...

Hence then, the article about hansa biopharma announces positive reimbursement decision for idefirix imlifidase in belgium as desensitization treatment for highly sensitized patients in kidney transplantation was published today ( Thursday 01/06/2023 - 09:21 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Hansa Biopharma announces positive reimbursement decision for Idefirix (imlifidase) in Belgium as desensitization treatment for highly sensitized patients in kidney transplantation )

Also on site :

• Prominent Canadian Musician Says Gig Was Cancelled After Google AI Overview Wrongly Branded Him Sex Pest
• Goldman Sachs expects layoffs to keep rising—and says investors are punishing the stocks of companies that slash staff
• Five killed in helicopter crash on Africa’s highest mountain (VIDEO)